161:
Historically, subcutaneous panniculitis-like T-cell lymphoma, as with other types of T-cell lymphoma, was treated similarly to B-cell lymphomas. However, in recent years, scientists have developed techniques to better recognize the different types of lymphomas, such as PTCL. It is now understood that
129:
Subcutaneous panniculitis-like T-cell lymphoma is a rare type of lymphoma that infiltrates the subcutaneous fat but does not involve the skin. There are two subtypes – alpha-beta and gamma-delta. Patients with the gamma-delta subtype have a more aggressive clinical course.
313:
Kong, YY.; Dai, B.; Kong, JC.; Zhou, XY.; Lu, HF.; Shen, L.; Du, X.; Shi, DR. (Oct 2008). "Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathologic, immunophenotypic, and molecular study of 22 Asian cases according to WHO-EORTC classification".
680:
200:
Pralatrexate is one compound currently under investigation to add to the frontline treatment of PTCL. It is currently approved by the FDA for relapsed or refractory T cell lymphoma. Side effects include mouth sores, which can be severe.
464:
Corradini P, Tarella C, Zallio F, et al. (September 2006). "Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation".
429:
Rodríguez J, Conde E, Gutiérrez A, et al. (July 2007). "Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group".
589:"Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol—a groupe d'Etude des lymphomes de l'Adulte study"
162:
PTCL behaves differently from B-cell lymphomas and therapies are being developed that specifically target these types of lymphoma. Currently, however, there are no drugs approved by the
390:"Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma"
552:
Deconinck E, Lamy T, Foussard C, et al. (June 2000). "Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial".
75:") is a cutaneous condition that most commonly presents in young adults, and is characterized by subcutaneous nodules. Common symptoms include fever, fatigue, and
743:
626:
Rojnuckarin, P.; Nakorn, TN.; Assanasen, T.; Wannakrairot, P.; Intragumtornchai, T. (Mar 2007). "Cyclosporin in subcutaneous panniculitis-like T-cell lymphoma".
163:
249:
351:"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study"
124:
96:
210:
112:
692:
37:
186:. Novel approaches to the treatment of PTCL in the relapsed or refractory setting are under investigation.
721:
57:
179:
119:
and T-cells. PTCL specifically affects T-cells, and results when T-cells develop and grow abnormally.
183:
189:
182:
are commonly offered as the initial therapy. Some patients may receive an autologous or allogeneic
515:"Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma"
588:
514:
350:
643:
608:
569:
534:
482:
446:
411:
370:
331:
295:
245:
47:
27:
635:
600:
561:
526:
474:
438:
401:
362:
323:
287:
215:
134:
737:
565:
442:
175:
167:
76:
697:
327:
174:, which are both approved by the FDA for relapsed or refractory T cell lymphoma.
604:
220:
99:. Peripheral T-cell lymphoma (PTCL) is defined as a diverse group of aggressive
639:
291:
171:
366:
530:
406:
389:
100:
647:
612:
573:
538:
486:
478:
450:
415:
374:
335:
299:
123:
716:
108:
672:
116:
104:
684:
278:
Vose JM (October 2008). "Peripheral T-cell non-Hodgkin's lymphoma".
266:
WHO Classification of
Tumours of Haematopoietic and Lymphoid Tissues
111:) (see figure for an overview of PTCL subtypes). PTCL is a type of
150:
146:
587:
Haioun C, Lepage E, Gisselbrecht C, et al. (August 2000).
349:
Reimer P, Rüdiger T, Geissinger E, et al. (January 2009).
115:(NHL). NHL affects two particular types of white blood cells:
142:
138:
513:
Gisselbrecht C, Lepage E, Molina T, et al. (May 2002).
240:
James, William D.; Berger, Timothy G.; et al. (2006).
62:
Lupus panniculitis, cutaneous gamma delta T Cell lymphoma
388:
Mercadal S, Briones J, Xicoy B, et al. (May 2008).
103:
that develop from mature-stage white blood cells called
52:
Requires biopsy confirmation by expert hemopathologist
662:
707:
666:
242:
56:
46:
36:
26:
21:
166:(FDA) specifically for PTCL. There are two drugs,
93:Subcutaneous panniculitis-like T-cell lymphoma
8:
663:
18:
405:
232:
192:or CHOP-like regimens have been used.
744:Lymphoid-related cutaneous conditions
7:
14:
164:U.S. Food and Drug Administration
73:panniculitis-like T-cell lymphoma
566:10.1046/j.1365-2141.2000.02098.x
443:10.1111/j.1600-0609.2007.00856.x
122:
280:Hematol. Oncol. Clin. North Am
1:
42:HPS (hemophagocytic syndrome)
328:10.1097/PAS.0b013e31817a9081
69:Subcutaneous T-cell lymphoma
32:Oncology, cutaneous oncology
22:Subcutaneous T-cell lymphoma
605:10.1200/JCO.2000.18.16.3025
760:
107:and natural killer cells (
97:peripheral T-cell lymphoma
640:10.1080/10428190601078456
292:10.1016/j.hoc.2008.07.010
211:Cutaneous T-cell lymphoma
367:10.1200/JCO.2008.17.4870
531:10.1200/JCO.2002.02.125
479:10.1038/sj.leu.2404306
113:non-Hodgkin's lymphoma
58:Differential diagnosis
407:10.1093/annonc/mdn022
244:. Saunders Elsevier.
180:chemotherapy regimens
184:stem cell transplant
133:It is described as
708:External resources
499:d’Amore F, et al.
286:(5): 997–1005, x.
153:usually negative.
71:(also known as a "
731:
730:
251:978-0-7216-2921-6
66:
65:
48:Diagnostic method
16:Medical condition
751:
664:
652:
651:
623:
617:
616:
584:
578:
577:
549:
543:
542:
510:
504:
497:
491:
490:
461:
455:
454:
431:Eur. J. Haematol
426:
420:
419:
409:
385:
379:
378:
346:
340:
339:
322:(10): 1495–502.
316:Am J Surg Pathol
310:
304:
303:
275:
269:
262:
256:
255:
237:
216:Lennert lymphoma
126:
95:is a subtype of
19:
759:
758:
754:
753:
752:
750:
749:
748:
734:
733:
732:
727:
726:
703:
702:
675:
661:
656:
655:
625:
624:
620:
599:(16): 3025–30.
586:
585:
581:
554:Br. J. Haematol
551:
550:
546:
512:
511:
507:
498:
494:
463:
462:
458:
428:
427:
423:
387:
386:
382:
348:
347:
343:
312:
311:
307:
277:
276:
272:
263:
259:
252:
239:
238:
234:
229:
207:
198:
159:
90:
85:
17:
12:
11:
5:
757:
755:
747:
746:
736:
735:
729:
728:
725:
724:
712:
711:
709:
705:
704:
701:
700:
689:
676:
671:
670:
668:
667:Classification
660:
659:External links
657:
654:
653:
618:
593:J. Clin. Oncol
579:
544:
525:(10): 2472–9.
519:J. Clin. Oncol
505:
492:
456:
421:
380:
355:J. Clin. Oncol
341:
305:
270:
257:
250:
231:
230:
228:
225:
224:
223:
218:
213:
206:
203:
197:
194:
158:
155:
89:
88:Classification
86:
84:
81:
64:
63:
60:
54:
53:
50:
44:
43:
40:
34:
33:
30:
24:
23:
15:
13:
10:
9:
6:
4:
3:
2:
756:
745:
742:
741:
739:
723:
719:
718:
714:
713:
710:
706:
699:
695:
694:
690:
687:
686:
682:
678:
677:
674:
669:
665:
658:
649:
645:
641:
637:
633:
629:
628:Leuk Lymphoma
622:
619:
614:
610:
606:
602:
598:
594:
590:
583:
580:
575:
571:
567:
563:
560:(4): 736–42.
559:
555:
548:
545:
540:
536:
532:
528:
524:
520:
516:
509:
506:
503:2006;108:A401
502:
496:
493:
488:
484:
480:
476:
473:(9): 1533–8.
472:
468:
460:
457:
452:
448:
444:
440:
436:
432:
425:
422:
417:
413:
408:
403:
400:(5): 958–63.
399:
395:
391:
384:
381:
376:
372:
368:
364:
361:(1): 106–13.
360:
356:
352:
345:
342:
337:
333:
329:
325:
321:
317:
309:
306:
301:
297:
293:
289:
285:
281:
274:
271:
267:
264:Swerdlow SH,
261:
258:
253:
247:
243:
236:
233:
226:
222:
219:
217:
214:
212:
209:
208:
204:
202:
195:
193:
191:
187:
185:
181:
177:
176:Anthracycline
173:
169:
165:
156:
154:
152:
148:
144:
140:
136:
131:
127:
125:
120:
118:
114:
110:
106:
102:
98:
94:
87:
82:
80:
78:
74:
70:
61:
59:
55:
51:
49:
45:
41:
39:
38:Complications
35:
31:
29:
25:
20:
715:
691:
679:
634:(3): 560–3.
631:
627:
621:
596:
592:
582:
557:
553:
547:
522:
518:
508:
500:
495:
470:
466:
459:
434:
430:
424:
397:
393:
383:
358:
354:
344:
319:
315:
308:
283:
279:
273:
265:
260:
241:
235:
199:
188:
178:-containing
168:Pralatrexate
160:
132:
128:
121:
92:
91:
77:pancytopenia
72:
68:
67:
437:(1): 32–8.
221:Skin lesion
394:Ann. Oncol
227:References
172:Romidepsin
157:Treatment
101:lymphomas
83:Diagnosis
28:Specialty
738:Category
717:Orphanet
648:17454599
613:10944137
574:10929023
539:12011124
487:16871285
467:Leukemia
451:17598836
416:18303032
375:19029417
336:18708940
300:18954748
205:See also
196:Research
145:+, with
109:NK cells
698:C537503
688:: C83.6
117:B-cells
105:T-cells
646:
611:
572:
537:
501:Blood.
485:
449:
414:
373:
334:
298:
268:, 2008
248:
722:86884
693:MeSH
644:PMID
609:PMID
570:PMID
535:PMID
483:PMID
447:PMID
412:PMID
371:PMID
332:PMID
296:PMID
246:ISBN
190:CHOP
170:and
151:CD56
149:and
147:CD30
681:ICD
636:doi
601:doi
562:doi
558:109
527:doi
475:doi
439:doi
402:doi
363:doi
324:doi
288:doi
143:CD8
139:CD4
135:CD3
740::
720::
696::
685:10
642:.
632:48
630:.
607:.
597:18
595:.
591:.
568:.
556:.
533:.
523:20
521:.
517:.
481:.
471:20
469:.
445:.
435:79
433:.
410:.
398:19
396:.
392:.
369:.
359:27
357:.
353:.
330:.
320:32
318:.
294:.
284:22
282:.
141:-/
137:+/
79:.
683:-
673:D
650:.
638::
615:.
603::
576:.
564::
541:.
529::
489:.
477::
453:.
441::
418:.
404::
377:.
365::
338:.
326::
302:.
290::
254:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
